Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| (NASDAQ: APVO) | Delayed: 1.49 -0.12 (7.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.61 | 52 Week High | $4.33 | |||
| Open | $1.74 | 52 Week Low | $1.80 | |||
| Day High | $1.74 | P/E | N/A | |||
| Day Low | $1.43 | EPS | $0.00 | |||
| Volume | 123,207 | |||||
